Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Now's the Time for Low-Debt Stocks to Pay Off
10:32am, Monday, 09'th May 2022
Companies with high debt lived in a sort of paradise in 2019 to 2021. With interest rates extraordinarily low, their debt burden didn't hurt.
Is Gilead Sciences Too Dependent On These 2 Areas of Its Business?
11:05am, Sunday, 08'th May 2022 The Motley Fool
Gilead is still, by and large, an HIV company.
Is Gilead Sciences Too Dependent On These 2 Areas of Its Business?
07:05am, Sunday, 08'th May 2022
Gilead is still, by and large, an HIV company.
Gilead Sciences: A Forgotten Company
06:57am, Friday, 06'th May 2022
Gilead Sciences has been forgotten, as the once promising growth potential has disappeared. The company has handled the LOE for its HIV assets well, and is continuing to see overall revenue increase a
Ligand (LGND) Q1 Earnings Beat, OmniAb Spin-Off on Track
03:22pm, Thursday, 05'th May 2022 Zacks Investment Research
Ligand (LGND) reports encouraging first-quarter 2022 numbers by beating estimates on both counts. However, Captisol sales get hurt by lower demand for COVID-19 therapies.
Biotech Stock Roundup: BIIB & GILD's Earnings Update, VRTX Down on Regulatory News
05:39pm, Wednesday, 04'th May 2022 Zacks Investment Research
Earnings and regulatory updates from Bristol Myers (BMY), among others, and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.
Should You Invest in the iShares Biotechnology ETF (IBB)?
10:20am, Wednesday, 04'th May 2022 Zacks Investment Research
Sector ETF report for IBB
Why the 5 Highest-Yielding Nasdaq Stocks May Be the Best and Safest Value Buys Now
07:16am, Tuesday, 03'rd May 2022
The Nasdaq has been absolutely obliterated this year, down a stunning 21.2%, which puts the tech-heavy index firmly in bear market territory.
Should I buy Gilead Sciences shares in May 2022?
02:20pm, Monday, 02'nd May 2022
Gilead Sciences, Inc. (NASDAQ: GILD) shares have weakened from $72.27 to $57.19 since the beginning of January 2022, and the current price stands around $59.39. Gilead Sciences reported better than ex
Top Stocks To Help Prepare For A Recession - We Recommend Gilead Sciences
01:08pm, Monday, 02'nd May 2022
We think a serious recession is more likely than not, with the signs of crisis and dislocation already showing themselves. In big focus are rates, and the house view is that they'll have to rise more
Top Pharmaceutical Stocks To Watch In May 2022
09:45am, Saturday, 30'th Apr 2022
Check out these pharmaceutical stocks in the stock market today.
Why These Analysts Are Bullish On Gilead's Q1 Earnings
05:57pm, Friday, 29'th Apr 2022 Benzinga
RBC Capital Market views Gilead Sciences Inc's (NASDAQ: GILD) Q1 as a solid quarter, with a bottom-line beat reflecting Veklury cash flow boost, solid core business performance despite seasonal hea
Where Gilead Sciences Stands With Analysts
04:05pm, Friday, 29'th Apr 2022 Benzinga
Over the past 3 months, 11 analysts have published their opinion on Gilead Sciences (NASDAQ:GILD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding
Gilead (GILD) Q1 Earnings Beat on Solid COVID Treatment Sales
03:05pm, Friday, 29'th Apr 2022 Zacks Investment Research
Gilead (GILD) beats on earnings and revenues in the first quarter on strong Veklury sales. HIV business maintains momentum on Biktarvy.
Why These Analysts Are Bullish On Gilead's Q1 Earnings
02:10pm, Friday, 29'th Apr 2022
RBC Capital Market views Gilead Sciences Inc's (NASDAQ: GILD) Q1 as a solid quarter, with a bottom-line beat reflecting Veklury cash flow boost, solid core business performance despite seasonal hea
